logo

Clinical Trial Results

Share

Biotechnology company Rigel Pharmaceuticals, Inc. (RIGL) announced Tuesday positive topline results from a multi-center, Phase 2 clinical trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized patients with COVID-19. The trial,...

Sage Therapeutics Inc. (SAGE) and Biogen Inc. (BIIB) said that phase 2 KINETIC Study, which evaluated SAGE-324 in the treatment of people with essential tremor, achieved its primary endpoint of a statistically significant reduction from baseline compared to placebo in The Essential Tremor Rating Assessment...

British drug major AstraZeneca Plc (AZN, AZN.L) Monday announced that its DARE-19 Phase III trial for Farxiga (dapagliflozin) in COVID-19 did not achieve statistical significance for the primary endpoint of prevention measuring organ dysfunction and all-cause mortality. The trial also failed to achieve...

Merck & Co. Inc. (MRK), known as MSD outside the U.S. and Canada, announced Thursday that the pivotal Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, met its primary endpoint of disease-free survival (DFS) for the potential adjuvant treatment of patients with renal cell carcinoma...

The University of Oxford reported on Tuesday that it is halting the trial of the COVID vaccine developed by AstraZeneca PLC (AZN) on children and teenagers. The vaccine, developed in collaboration with AstraZeneca and Oxford, is under scrutiny for resulting in blood clots in the recipients. The...

CytoDyn Inc. (CYDY.OB), a late-stage biotechnology company developing Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, has filed a new protocol to extend treatment to four weeks for critically ill COVID-19 patients. The company will initiate patient...

asianstocks2 dec16 31mar21 AzurRx BioPharma Inc.'s (AZRX) phase IIb study of MS1819 for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis did not consistently meet the primary efficacy endpoint.

pfizerbiontech march31 Pfizer Inc. (PFE) and BioNTech's (BNTX) COVID-19 vaccine BNT162b2 has demonstrated 100% efficacy and robust antibody responses in a phase III trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection, the companies said in a statement.

Wave Life Sciences Ltd. (WVE) has decided to stop clinical development of its Huntington's disease drug candidates - WVE-120101 and WVE-120102.

Humanigen Inc. (HGEN) said Monday that its lead drug candidate, lenzilumab, improved the relative likelihood of survival without need for invasive mechanical ventilation by 54%, achieving the primary endpoint of the phase 3 study. The clinical improvement was observed over and above other treatments,...

Boston Scientific Corp. (BSX) Thursday announced positive data from study of the TheraSphere Y-90 Glass Microspheres, a type of radioembolization comprised of millions of microscopic glass beads containing radioactive yttrium. The study evaluated the safety and efficacy of TheraSphere therapy in patients...

Myovant Sciences (MYOV) and Pfizer Inc. (PFE) reported positive data from the phase 3 LIBERTY randomized withdrawal study of relugolix combination therapy in women with uterine fibroids. The data showed the potential value of continued treatment for women with uterine fibroids, with those receiving relugolix...

Swiss drug major Novartis AG (NVS) announced Tuesday positive result from its phase III VISION study evaluating the efficacy and safety of radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer. The trial met both primary endpoints of overall survival and radiographic progression-free...

Regeneron Pharmaceuticals Inc.'s (REGN) antibody cocktail REGEN-COV (casirivimab with imdevimab) reduced hospitalization or death by 70% in Non-hospitalized COVID-19 Patients, as per a late-stage trial result. The antibody Cocktail also significantly shortened the duration of symptoms by 4 days. The...

astrazeneca feb25 22mar21 British drug major AstraZeneca Plc announced positive late-stage trial results of its covid-19 vaccine AZD1222 in the United States. The company said the U.S. trial met the primary efficacy endpoint in preventing COVID-19 at interim analysis. It demonstrated statistically significant vaccine efficacy of 79 percent at preventing symptomatic COVID-19 and 100 percent efficacy at preventing severe...

Follow RTT